Ultromics will offer its artificial intelligence driven EchoGo Pro as a stress-echo module in the EchoGo suite alongside EchoGo Core, its AI solution for automated systolic function and strain analysis. The EchoGo suite is a cloud-based service that uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site.
January 6, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Ultromics' EchoGo Pro, an artificial intelligence (AI) powered, outcomes-driven, decision support tool to automatically identify coronary artery disease (CAD) in echocardiograms.
CAD indications can be subtle. Misdiagnosis happens with one in five patients potentially resulting in poor treatment and outcomes, which is compounded by the subjectivity of interpretation between clinicians. With the use of EchoGo Pro, clinicians have additional insights, derived from AI models trained on large datasets in Oxford, U.K. The technology improves disease prediction and supports more accurate diagnosis. This should lead to earlier suitable interventions, reducing cardiac events and improving patient care.
"Coronary artery disease is a huge global burden, affecting tens of millions of peoples' lives worldwide," said Ross Upton, Ph.D., founder and CEO of Ultromics. "Heart disease is the biggest killer globally and this number is increasing daily. Our goal is to help doctors detect CAD more accurately, improving patient outcomes and saving lives."
Ultromics will offer EchoGo Pro as a stress-echo module in the EchoGo suite alongside EchoGo Core, its AI solution for automated systolic function and strain analysis. The EchoGo suite is a cloud-based service that uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site. By automating echocardiogram analysis as part of a cloud service, Ultromics hopes to save clinicians even more time when compared to traditional on-site solutions.
"COVID-19 has placed an even greater pressure on cardiac care and looks likely to have lasting implications in terms of its impact on the heart" explained Upton. "The healthcare industry needs to quickly pivot towards AI powered automation to reduce the time to diagnosis and improve patient care. To help support this shift and save countless lives we are making the EchoGo suite as complete and automated as possible to help clinicians rapidly assess disease and provide early, appropriate intervention. FDA approval for EchoGo Pro is the next step on our innovation journey to transform echocardiography and impact patients' lives"
EchoGo Pro is now clinically available in the European Union and U.S., and is being rolled out in the U.K. National health Service (NHS) as part of the prestigious NHSx award and assessed at Mayo Clinic.
Ultromics is a global health technology firm which provides autonomous echocardiography analysis through innovative AI solutions. The company developed the first fully automated solution for echocardiography and strain analysis. The platform, EchoGo, is a cloud-based AI service which delivers analysis to any vendor within minutes and with zero variability through its zero-click, full automation workflow. The technology was developed at the University of Oxford and built-in partnership with the NHS and has since raised over £20 million to help bring diagnostic quality to hospitals, improve patient care, and help make valuable resource and cost savings.
For more information: www.ultromics.com